Trial: 201909052

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC# 776864) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Phase

III

Principal Investigator

Thaker, Premal

Disease Site

Other Female Genital; Ovary

Learn more about this study at: clinicaltrials.gov